Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12139476 | 0.86 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL11484541 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL14417429 | 0.82 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL9417290 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL9669244 | 0.80 | ALDH1A1 (0.47) | ALDH1A1MAPTKDM4EMAPK1MEN1 | |
| SCHEMBL14331559 | 0.79 | ALDH1A1 (0.43) | ALDH1A1MAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL8990966 | 0.79 | HTR2A (0.43) | ALDH1A1MAPTKDM4EMAPK1NPSR1 | |
| SCHEMBL12818446 | 0.77 | ADRA2A (0.41) | ALDH1A1MAPTKDM4EMAPK1HPGD | |
| SCHEMBL31027936 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EMAPK1MEN1 | |
| SCHEMBL4404407 | 0.76 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EMAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338412-B2 | Inhibitors of P38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110281878-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110160163-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-30 | — | — | US | disclosed |
| US-7951809-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-05-31 | — | — | US | disclosed |
| US-7919513-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-05 | — | — | US | disclosed |
| US-7919513-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-05 | — | — | US | disclosed |
| US-20090318452-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318452-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-24 | — | — | US | disclosed |
| US-7598277-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090203702-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-08-13 | — | — | US | disclosed |
| EP-0889036-A1 | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5852043-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-12-22 | — | — | US | disclosed |
| US-5846993-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-12-08 | — | — | US | disclosed |
| US-5834467-A | AIDS TREATMENT; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-11-10 | — | — | US | disclosed |
| US-5827859-A | ADMINISTERED TO TREAT AIDS; VIRICIDES | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5827891-A | FOR TREATMENT OF AIDS, BLOCKING REPLICATION OF HIV VIRUS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5827858-A | ADMINISTERED TO TREAT AIDS | AGOURON PHARMACEUTICALS, INC. | 1998-10-27 | — | — | US | disclosed |
| US-5824688-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 1998-10-20 | — | — | US | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160163-A1 | INHIBITORS OF p38 | ZAP70, MAPK1, MAP3K20 | ALDH1A1 3654/4885MAPT 3056/4885KDM4E 2410/4885 |
| US-20110281878-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | ALDH1A1 3189/4885MAPT 1883/4885KDM4E 3426/4885 |
| US-20090318452-A1 | INHIBITORS OF p38 | ZAP70, MAPK1, MAP3K20 | ALDH1A1 3654/4885MAPT 3056/4885KDM4E 2410/4885 |
| US-20090203702-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | ALDH1A1 3189/4885MAPT 1883/4885KDM4E 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.